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The Korean National Health Insurance revised its reimbursement criteria to expand cover-
age for anti-osteoporotic drug treatments in 2011 (expanding diagnostic criteria and the
coverage period for anti-osteoporotic therapy) and 2015 (including osteoporotic fracture
patients regardless of bone mineral density). We examined whether the two revisions
contributed to an increase in the prescription rates of anti-osteoporotic drugs in Korea.
Methods
We used the Health Insurance Review and Assessment Service-National Patient Sample
data from 2010 through 2016. A segmented regression analysis of interrupted time series
was performed to assess changes in the monthly prescription rates of anti-osteoporotic
drugs among women aged 50 or older, defined as the proportion of elderly women pre-
scribed with anti-osteoporotic drugs.
Results
Both the levels (i.e., abrupt jump or drop) and the trends (i.e., slope) of the prescription rates
of anti-osteoporotic drugs in the general population, osteoporotic patients, and osteoporotic
fracture patients showed no significant changes after the first revision. However, there was
a significant increase in the trends in the general population (β = 0.0166, p = 0.0173) and in
osteoporotic patients (β = 0.1128, p = 0.0157) after the second revision. Women aged 65 to
79 years were the most significantly increased group in terms of the treatment proportion
after the second revision because the trend was significant after the second revision in all
three study populations (β = 0.0300, 0.1212, 0.1392, respectively; p < 0.05).
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Conclusions
Although the two revisions expanded reimbursement coverage, only the second revision on
reimbursing based on osteoporotic fracture regardless of bone mineral density was associ-
ated with increasing the proportion of post-menopausal women being treated with anti-oste-
oporotic drugs.
Introduction
Osteoporosis, characterized by a reduced density and quality of bone, is one of the major
chronic conditions in the elderly population and is a significant risk factor for fractures among
elderly individuals. The International Osteoporosis Foundation estimates that over 200 million
women worldwide suffer from osteoporosis—approximately one-tenth of women aged 60,
one-fifth of women aged 70, two-fifths of women aged 80, and two-thirds of women aged 90
years. Moreover, one of three women over 50 years of age will experience osteoporotic frac-
tures. The incidences of osteoporosis and fracture increase with age and elderly osteoporotic
women are at high risk of fracture [1]. It is important to treat osteoporosis to prevent fractures
in postmenopausal women because it was reported that single bone mineral density (BMD)
and past fracture were predictors of long-term fracture incidence [2]. While bisphosphonates
as mainly used in anti-osteoporotic therapy show evidence for “broad-spectrum” anti-fracture
efficacy, concern about atypical femur fractures occurrence after treatment was addressed.
Therefore, anti-osteoporotic drug therapy should be used according to the benefit/harm ratio
in individual patients [3,4].
With an increasing awareness that osteoporosis is a major risk factor for fractures in the
elderly, the Korean National Health Insurance (NHI) after 1998 began to reimburse costs for
anti-osteoporotic drug treatments to prevent osteoporotic fractures. However, the reimburse-
ment criterion for anti-osteoporotic drugs, which was a T-score� −3.0, was below the diag-
nostic criteria of osteoporosis (i.e., a T-score� −2.5) [5]. Also, anti-osteoporotic drugs were
reimbursed for only six months, although long-term drug therapy is necessary [6–9]. Such lim-
ited reimbursement by the NHI was criticized because prescription of anti-osteoporotic drugs
applying such criteria was not effective in preventing osteoporotic fractures.
In response to these concerns, the NHI reimbursement guidelines for anti-osteoporotic
drugs were revised in October 2011 (first revision) and then in May 2015 (second revision),
with the aim of preventing primary and secondary osteoporotic fractures in an aging society.
In the first revision, the reimbursement criterion and period for anti-osteoporotic drug
treatments were respectively expanded from T-score � −3.0 to� −2.5 and from six months
to one year, in order to treat osteoporotic patients earlier and allow for more prolonged ther-
apy. Through the second revision, the anti-osteoporotic drug could be reimbursed for three
years, regardless of the level of the T-score, if an osteoporotic fracture was diagnosed by X-
ray (Fig 1).
However, there has been no empirical study to assess the effectiveness of the revised NHI
reimbursement guidelines for anti-osteoporotic drugs in Korea. Therefore, we conducted this
study, analyzing the changes of prescription rates of anti-osteoporotic drugs after the revision
of the reimbursement guidelines, to examine whether the NHI reimbursement expansion was
associated with improving the opportunities for Korean women with osteoporosis to receive
drug treatment.
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Materials and methods
Data sources
This study used data from the Health Insurance Review and Assessment Service-National
Patient Sample (HIRA-NPS) in Korea from 2010 through 2016. Each year, a 3% random sam-
ple (approximately 1.4 million persons) of the entire population, stratified by the total of 32
groups according to sex (2 strata) and age (16 strata), are selected, and their NHI claims rec-
ords from the relevant year are included in the HIRA-NPS data. All patient data in HIRA-NPS
were fully anonymized to ensure privacy [10]. Korea has a National Health Security System
with two tiers: the NHI and Medical Aid (MA) programs (97% and 3% of the population,
respectively). Both NHI and MA beneficiaries are sampled in HIRA-NPS, and the reimburse-
ment revision for anti-osteoporotic drug therapy was applied both to the NHI and to the MA
beneficiaries [11]. The research protocol was approved by the Institutional Review Board of
Yonsei University (IRB No. 7001988-201803-HR-329-01E). The need for informed consent
from the study population was waived by the board.
Study population
Patients with osteoporosis and/or osteoporotic fracture are directly benefited by the changes of
the first and second reimbursement policies. Therefore, we analyzed the impact of the policy
among three different study populations. First, women aged 50 years or older as a reference
were defined as the general population (GP). Second, women aged 50 years or older with a
record of a diagnosis of osteoporosis [International Classification of Diseases code, 10th
revision (ICD-10): M80, M81, and M82] were defined as osteoporotic patients (OP). Third,
women aged 50 years or older with a record of a diagnosis of osteoporotic fracture were
defined as osteoporotic fracture patients (OFP). Based on previous studies that defined osteo-
porotic fractures using diagnosis codes from claims records [12–16], we defined the following
fractures as osteoporotic fractures: hip fractures (S72.0 and S72.1); spine fractures (S22.0,
S22.1, S32.0, M48.4 and M48.5); distal radius fractures (S52.5 and S52.6); cervical fractures
(S42.0); humerus fractures (S42.2 and S42.3); and distal tibia fractures (S82.3, S82.5 and S82.6).
Anti-osteoporotic drugs in this study included drugs indicated for osteoporosis treatment
under the approved label and reimbursed by NHI during the study period. Specific drugs
included the following: bisphosphonates (alendronate, etidronate, ibandronate, pamidronate,
risedronate and zoledronate); bisphosphonate/vitamin D combination (alendronate/calcitriol,
alendronate/cholecalciferol, ibandronate/cholecalciferol and risedronate/cholecalciferol);
selective estrogen receptor modulator (bazedoxifene and raloxifene); and active vitamin D
Fig 1. Revisions of the National Health Insurance reimbursement guideline for anti-osteoporotic drugs from 2010 to 2016.
https://doi.org/10.1371/journal.pone.0244759.g001
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(alfacalcidol and calcitriol). We searched approved drugs indicated for osteoporosis treatment
in the drug database of the Ministry of Food and Drug Safety and in the reimbursement guide-
lines for anti-osteoporotic drugs. Using nine-digit Korean Active Pharmaceutical Ingredients
codes listed by the HIRA, we identified specific anti-osteoporotic drugs from the HIRA-NPS
data for the analysis.
Measurements and data analysis
Although the ultimate goal of the policy was to prevent osteoporotic fractures, it is difficult
to measure the effectiveness of the policy in terms of the reduction of the incidence of osteo-
porotic fracture due to the long lag time between the drug therapy and its outcome of osteo-
porotic fracture prevention. Thus, alternatively, we chose to examine the prescription rate of
anti-osteoporotic drugs, which is a process measure that aims to capture the impact of the
policy within a short-term observation period following the policy change. We analyzed
whether the prescription rate, measured as the proportion of elderly women treated with
anti-osteoporotic drugs in each study group, increased after the revision. Time series data
were constructed by calculating the prescription rates at monthly time points during the
study period (S1 Table).
If individuals had claim records with prescriptions for anti-osteoporotic drugs, we consid-
ered them as being treated with anti-osteoporotic drugs. As a first step to investigate whether
there were noticeable changes in the prescription rates of anti-osteoporotic drugs following
the first and second reimbursement guideline revisions, in October 2011 and May 2015, we
visually inspected a plot of the prescription rate over time. More specifically, we inspected a
change in the levels of prescription rate (i.e., an abrupt jump or drop) after the implementation
of each revision. Also, we looked for a change in the trend of the prescription rates by looking
for increases or decreases in the slope of the segment after the revision as compared with the
segment preceding the revision.
To test whether the identified changes in the level and the trend of the prescription rates
were the result of chance or not, we conducted a segmented regression analysis of an inter-
rupted time series. Segmented regression analysis of interrupted time series is a powerful
statistical method to assess “how much an intervention changed an outcome of interest, imme-
diately and over time; instantly or with delay; and transiently or long-term.” This statistical
approach is appropriate if data can produce summarized outcome measures at regular, evenly
spaced intervals. However, its limitations include that changes may follow non-linear patterns
despite assuming a linear trend and individual-level covariates are not controlled [17]. Because
the effect of intervention and persistence over time can be confirmed by comparing levels and
trends measured in intervals, segmented regression analysis of interrupted time series has
been employed frequently in assessing policy effects over time [18–20]. Since our study had
access to time series data with monthly prescription rates of anti-osteoporotic drugs for 84
consecutive months from January 2010 through December 2016, we were able to assess the
impact of the reimbursement expansions using this approach.
We assessed the impacts of the first and the second revisions in the GP, OP, and OFP
groups. Because there are seasonal variations in the incidence of osteoporotic fracture [21–23],
we assumed that the prescription rates of anti-osteoporotic drugs would have seasonal varia-
tions as well. To control for the effect of seasonality on the dependent variable, we included
dummy variables for the seasons in the regression models. Furthermore, the autocorrelation
of error terms was detected by the Durbin-Watson test [17], and thus an autoregressive inte-
grated moving average (ARIMA) model with a second-order difference of independent vari-
ables was used to adjust the first-order autocorrelation. The statistical package SAS System for
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Windows, version 9.4 (SAS Inc., Cary, NC, USA) was used to perform the analyses in this
study.
Impacts of reimbursement guideline revisions may vary across different age groups because
osteoporosis and osteoporotic fractures are more prevalent in older groups. Thus, we stratified
the segmented regression analysis and compared the impacts of the reimbursement guideline
revisions among three age groups: 50–64, 65–79, and� 80 years old.
Results
Among the 1,819,062 women aged 50 years or above included in the 2010–2016 HIRA-NPS
data, 408,759 OP (22.5%) and 79,451 OFP (4.4%) were identified. The number of patients
prescribed anti-osteoporotic drugs was 211,384 (51.7%) in OP and 17,523 (22.1%) in OFP.
Table 1 shows the baseline characteristics of the study population in January 2010. The
highest proportions among the three age groups were observed in the 65–79 years age group
of OP (57.56%) and OFP (50.02%), and the 50–64 years age group of GP (53.29%). The major-
ity of the patients were enrolled in the NHI (92.59% among GP, 86.75% among OP and
88.37% among OFP). The proportions in medical institutions and specialty areas were slightly
different across the three study population groups due to disease characteristics. The propor-
tion of patients who were treated in the clinic was higher in GP (77.52%) and in OP (73.78%)
than in OFP (58.16%). Also OFP were mainly treated by an orthopedics department (48.59%),
while GP and most of the OP were treated by internal medicine (38.41% and 33.40%,
respectively).
Fig 2 presents the monthly prescription rates from 2010 through 2016, with 84 data points
that were defined as the proportion of women prescribed anti-osteoporotic drugs. Through
Table 1. Baseline characteristics of patients with osteoporosis and osteoporotic fracture (January 2010).
General population Osteoporotic patients Osteoporotic fracture
patients
N % N % N %
Total 161,306 100.00 16,387 100.00 2,519 100.00
Age (years)
50–64 85,959 53.29 5,230 31.92 735 29.18
65–79 61,842 38.34 9,432 57.56 1,260 50.02
�80 13,505 8.37 1,725 10.53 524 20.80
Type of National Health Security Program enrolled
National Health Insurance 149,357 92.59 14,215 86.75 2,226 88.37
Medical aid 11,949 7.41 2,172 13.25 293 11.63
Type of health care institution treating osteoporosis or osteoporotic fracture
Tertiary hospital 7,176 4.45 867 5.29 126 5.00
General hospital 10,428 6.46 1,468 8.96 388 15.40
Hospital 10,486 6.50 1,403 8.56 510 20.25
Clinic 125,040 77.52 12,090 73.78 1,465 58.16
Health center 8,176 5.07 559 3.41 30 1.19
Specialty of clinicians treating osteoporosis or osteoporotic fracture
Internal medicine 61,954 38.41 5,473 33.40 449 17.82
Orthopedics 23,515 14.58 4,441 27.10 1,224 48.59
Family medicine 5,371 3.33 655 4.00 69 2.74
Neurosurgery 2,810 1.74 538 3.28 196 7.78
Others 67,656 41.94 5,280 32.22 581 23.07
https://doi.org/10.1371/journal.pone.0244759.t001
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direct observation, we can see that the proportion of OP treated with anti-osteoporotic drugs
increased for approximately one year after the first revision and then decreased to the level
seen before the first revision. About 6 months after the second revision, the prescription rate
began to increase, and the increasing trend continued for one year until the censoring point of
December 2016. A different trend was observed for OFP. There was no increase in the propor-
tion of OFP treated by anti-osteoporotic drugs after the first revision, and, instead, the propor-
tion continued to decrease. However, similar to the OP, the prescription rate started
increasing about 6 months after the second revision and continued to increase.
Table 2 presents the regression analysis results of our study. For all three populations, there
was no significant month-to-month change in the prescription rate of anti-osteoporotic drugs
before the first revision [p-value for baseline trend (β1): 0.6215 for GP, 0.6046 for OP and
0.4416 for OFP, respectively]. There was no significant change in the prescription rate of anti-
osteoporotic drugs after either the first [p-value for level change (β2): 0.3891, 0.9067 and
0.7070, respectively] or the second revision [p-value for level change (β4): 0.2454, 0.2734 and
0.6063, respectively]. While there was no significant change in the month-to-month trend
in the prescription rate of anti-osteoporotic drugs after the first revision [p-value for trend
change (β3): 0.3999, 0.5081 and 0.7297, respectively], there was a significant increase after
the second revision in trends for both GP and OP, but not for OFP [β5 = 0.0166, 0.1128 and
0.0931, respectively; and p-value for trend change (β5): 0.0173, 0.0157 and 0.0684,
respectively].
Segmented regression analysis was performed for the three age subgroups (50–64, 65–79,
and� 80 years old), respectively, to identify which groups were impacted by the revision of
the reimbursement guidelines (Table 3). None of the three age groups showed significant level
or trend changes after the first revision. This implies that the first reimbursement guideline
revision was not associated with expanding the number of people receiving anti-osteoporotic
drug therapy within any age group. On the other hand, the second revision showed significant
trend changes, with positive regression coefficients. In particular, in the 65–79 years old group,
Fig 2. Prescription rates of anti-osteoporotic drugs in women aged 50 or older in Korea.
https://doi.org/10.1371/journal.pone.0244759.g002
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all three study populations had significant increases in their prescription rates during the
period after the second revision (β5 = 0.0300, 0.1212, and 0.1392, respectively). The magnitude
of the regression coefficient was greatest in OFP (β5 = 0.1392), followed by OP (β5 = 0.1212)
and GP (β5 = 0.0300). For those above 80 years old, only OP had a significant increase in the
prescription rate during the period after the second revision (β5 = 0.1496).
Table 2. Results of the segmented regression analysis for the reimbursement revision’s effect on prescription rates of anti-osteoporotic drugs in women aged 50 or
older.
General population Osteoporotic patients Osteoporotic fracture patients
Coefficient p-value Coefficient p-value Coefficient p-value
β0 (intercept) 0.0823 0.3092 -0.1183 0.8264 1.4143 0.0196
β1 (TIME1, baseline trend) 0.0030 0.6215 0.0211 0.6046 -0.0346 0.4416
β2 (POLICY1, level change after the 1
st revision) 0.0761 0.3891 0.0691 0.9067 0.2444 0.7070
β3 (TIME2, trend change after the 1
st revision) -0.0054 0.3999 -0.0285 0.5081 0.0164 0.7297
β4 (POLICY2, level change after the 2
nd revision) -0.1084 0.2454 -0.6834 0.2734 -0.3534 0.6063
β5 (TIME3, trend change after the 2
nd revision) 0.0166 0.0173 0.1128 0.0157 0.0931 0.0684
β6 (Season1) -0.0524 0.3155 -0.1446 0.6779 -0.3535 0.3581
β7 (Season2) -0.2301 < 0.0001 -0.5848 0.0968 -0.7803 0.0454
β8 (Season3) -0.2243 < 0.0001 -0.0912 0.7922 -1.6506 < 0.0001
Durbin-Watson statistics 2.3769a 2.2387a 2.4372a
ap-value for the hypothesis of positive autocorrelation: > 0.05, p-value for the hypothesis of negative autocorrelation: > 0.05.
https://doi.org/10.1371/journal.pone.0244759.t002
Table 3. Results of segmented regression analysis of reimbursement revision effects on prescription rates for anti-osteoporotic drugs, according to age group.
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β1 (TIME1,
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0.0099a 0.0896 0.0880 0.0300a 0.1212a 0.1392a 0.0222 0.1496a 0.1035
β6 (Season1) 0.0033 -0.1904 -0.1411 -0.1204 -0.0309 -0.3141 -0.0590 -0.0324 -0.4197
β7 (Season2) -0.1006
a -0.1086 -0.3674 -0.4011a -0.6998 -0.8379 -0.3690a -1.1044a -0.6685
β8 (Season3) -0.0931
a 0.2886 -1.3283a -0.3942a -0.1146 -1.8482a -0.2673a -0.3593 -0.8996
Durbin-Watson
statistics
2.3761b 2.1839b 2.3378b 2.3157b 2.2059b 2.3851b 2.3594b 2.2940b 2.3011b
ap < 0.05.
bp-value for the hypothesis of positive autocorrelation: > 0.05, p-value for the hypothesis of negative autocorrelation: > 0.05.
https://doi.org/10.1371/journal.pone.0244759.t003
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Discussion
In this study, we evaluated the impacts of NHI reimbursement guideline revisions for anti-
osteoporotic drug therapy in Korea, which were intended to expand the NHI coverage for
osteoporotic patients with the goal of preventing osteoporotic fractures throughout the nation.
The segmented regression analysis results showed that the first revision, which expanded the
diagnostic criteria of osteoporosis from a T-score of −3.0 to −2.5 and increased the reimburse-
ment period from 6 months to 1 year after diagnosis, was not associated with expanding the
number of post-menopausal women aged 50 or older receiving anti-osteoporotic drug therapy.
This result implies that the first revision did not lead to an increase in the population benefit-
ting from osteoporosis treatment, and therefore it may not be an effective policy for reducing
the number of osteoporotic fractures in society.
The underlying reasons for this finding could be explained by the following. First, the
Korean NHI reimburses BMD tests performed to diagnose osteoporosis only for women aged
65 or older and men aged 70 or older [12]. Because women between the ages of 50 and 64 are
not subject to the reimbursement for the BMD test, they have a low chance to be diagnosed
and to have an opportunity to get treated. Second, the first revision set a restriction that BMD
had to be measured by DXA or quantitative computed tomography (QCT) tests on the central
bone. However, most osteoporotic patients in Korea are diagnosed by quantitative ultrasono-
gram (QUS) in clinics. Thus, even if the government relaxed the reimbursement criteria of
osteoporosis from a T-score of −3.0 to −2.5, the reimbursement restriction on the diagnostic
tests is an obstacle to receiving anti-osteoporotic drug therapy.
Unlike the first revised guideline, the second revision, which reimburses anti-osteoporotic
drug treatment for three years if the osteoporotic fracture was diagnosed by X-ray regardless
of the level of the T-score, appeared to be successful in increasing the number of patients
treated with anti-osteoporotic drug therapy. In women aged 50 or older, significant trend
changes in the prescription rates for anti-osteoporotic drugs were observed for GP (ß5 =
0.0166; p = 0.0173) and for OP (ß5 = 0.1128; p = 0.0157) after the implementation of the sec-
ond guideline revision. Our analysis suggests that the second revision has had the strongest
impact on increase of anti-osteoporotic drugs in women aged between 65 and 79 years. All
three study populations showed significant increases after the revision in the populations
treated with anti-osteoporotic drugs (ß5 = 0.0300, 0.1212 and 0.1392, and p = 0.0109, 0.0124
and 0.0483, respectively). This finding implies that a powerful driver in reimbursement guide-
lines to prescribe anti-osteoporotic drugs seems to be a fracture rather than t-score.
We performed a sensitivity analysis stratified according to the four types of anti-osteopo-
rotic drugs (i.e. bisphosphonates; bisphosphonate/vitamin D combination; selective estrogen
receptor modulator; and active vitamin D), in order to determine which specific anti-osteopo-
rotic drugs were most impacted by the revisions, and to assess the robustness of the primary
findings. Separate segmented regression analyses were performed with prescription rates of
each of the four drug classes set as dependent variables. As a result, only the prescription rate of
bisphosphonates among the four drug classes showed a significant trend change after the sec-
ond revision in general population (β5 = 0.0119, p = 0.0138) and in osteoporotic patients (β5 =
0.0695, p = 0.0470). This result is similar to the primary findings, confirming the robustness of
the primary findings. Because bisphosphonates were the most frequently prescribed anti-osteo-
porotic drugs in all of the three study populations during the study period (i.e., 56.0%-60.4% of
prescribed anti-osteoporotic drugs), it seems that the use of bisphosphonates was a main driver
in the prescription of anti-osteoporotic drugs among Korean elderly women.
Changes or external factors may potentially affect the prescription rates of anti-osteoporotic
drugs other than the reimbursement revisions, per se during the study period, which might
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impact the robustness of the primary findings of this study. First, several anti-osteoporotic
drugs are indicated for reasons other than osteoporosis. This might affect prescription rates of
anti-osteoporotic medications during the study period and distort the study results. To exam-
ine this issue, we analyzed the proportions of prescriptions of anti-osteoporotic drugs with
indications for other conditions than osteoporosis, which include some bisphosphonates such
as etidronate, pamidronate and zoledronate. The proportion of prescriptions for those drugs
relative to all drugs was 2.8% in the general population, 2.8% in the osteoporotic patients, and
4.3% in osteoporotic fracture patients, respectively. Because their proportion was very low, we
believed that the impact of these products on our study results would be very marginal. Sec-
ond, we checked the impact of new anti-osteoporotic drugs launched in the study period: baze-
doxifene in 2012 and ibandronate/cholecalciferol in 2013. The proportion of prescriptions of
those drugs out of all anti-osteoporotic drugs was very low (less than 5% even after the second
revision). Thus, we considered that the primary results of our study might not be affected by
the introduction of these new drugs. Third, BMD should be measured by DXA or QCT in
order to get reimbursed for anti-osteoporotic drugs. The prescription rates of anti-osteopo-
rotic drugs can be increased if the frequency of BMD tests increases. According to the analysis,
the rates of overall BMD testing in women aged 50 or older were similar after the first (96.8%)
and second revision (95.4%) respectively. Since the rate of BMD examination tests were main-
tained during the study period, we believe that the potential confounding effect of the increase
in the rate of BMD tests on the prescription rate of anti-osteoporotic drugs during the study
period would be very low.
There are a number of studies that have evaluated the effects of changes in reimbursement
guidelines for diagnostic tests or treatment for osteoporosis [24–26]. For example, in 2007,
Australia’s Medicare initiated reimbursement for DXA tests for elderly patients aged 70 or
older, designated as a high-risk group for fractures, in order to delay or prevent the occurrence
of fractures. The effect of this policy was evaluated by examining the changes in the proportion
of DXA tests and the incidence of fractures in two separate studies. When comparing DXA
test use before (2003–2006) and after (2007–2010) the introduction of the DXA reimburse-
ment guideline, the proportion of DXA referrals in both men and women significantly
increased, but that increase was small [24]. The changes of reimbursement guidelines had little
impact in reducing fracture incidence in elderly men and women, as fracture rates increased
in 2012 as compared to 2006 [25]. The Province of Ontario in Canada also changed its reim-
bursement policy for DXA tests in 2008. For the low-risk group, their NHI covered a DXA test
every two to three years, while it was covered annually for the high-risk group. Jaglal et al.
compared DXA test rates in adults aged 40 and older before and after the policy revision.
While the reduction in testing for low-risk groups was mainly a result of the effects intended
by the policy, it also showed a negative effect on the decrease among women within high-risk
populations [26].
In those studies, the effects of changes of reimbursement guidelines for DXA tests to diag-
nose osteoporosis were primarily assessed from the rates of DXA testing, which is a process
measure similar to the prescription rate measured in our study. Although the outcome mea-
sure, such as the rate of prevention of osteoporotic fracture, could be a more valid measure, it
requires long-term follow-up observation. Thus, process measures, often defined as health
care utilization rates rather than health outcomes, are used as an alternative method.
This study has several limitations. First, since this study used HIRA-NPS, the study subjects
were included based on the diagnosis records in the claims data. There is a possibility that
healthcare professionals entered diagnostic codes apart from the presence of the actual disease
to obtain reimbursement, which is an intrinsic limitation of administrative claims data and
may produce a bias. According to previous studies which assessed accuracy, correspondence
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between the major diagnosis of Health Insurance claims and medical records in Korea were
69.7% and 60.0% respectively [27,28]. Therefore, we may not rule out the possibility of discrep-
ancy in this study. Second, it included data for 20 months after the second guideline revision
because only data through 2016 were available publically. It may be difficult to determine
whether that is enough time to confirm the effects of the reimbursement guideline revision in
May 2015. However, if we extend the observation period further, it will be hard to distinguish
between the effect of the reimbursement guideline revision and that of the introduction of new
anti-osteoporotic drugs to the market on the increase in the prescription rates. For example,
the NHI started providing reimbursement for new anti-osteoporotic drugs, such as teripara-
tide and denosumab, from December 2016 and October 2017, respectively. Third, the impact
of the policy in this study was assessed with the number of patients treated with anti-osteopo-
rotic drugs as a process measure because the period following the revision of the second reim-
bursement guidelines was too short for assessing actual measurements of fractures as
outcomes. Fourth, an increasing rate of prescription of anti-osteoporotic drugs was found
after the second revision in May 2015, but not after the first revision in 2011. There could be
alternative explanation for this finding. For example, it is possible that both healthcare provid-
ers and patients became increasingly aware of the need for anti-osteoporosis treatment during
the 5-year period, and this increased awareness led to more adherence to the reimbursement
guidelines after the second revision. This might potentially confound the study findings. Lastly,
we attempted to confirm the impact of the reimbursement revisions with multiple compari-
sons by analyzing three study populations separately, by conducting stratified analysis accord-
ing to the three age groups, and by analyzing each of the four drug classes separately. However,
there is a possibility that our analysis did not account for multiple comparisons that might
affect the robustness of the primary findings. For example, the impact of the revisions may
vary across different types of healthcare organizations (i.e., clinics, general hospitals, or tertiary
care hospitals), different regions (i.e., big cities or small towns), or different types of programs
enrolled under the National Health Security (i.e., National Health Insurance or Medical Aid).
In future studies, more subgroup analyses or multiple comparisons may help confirm the
robustness of our findings and in identifying target groups that do not benefit from the revi-
sion and are therefore in the need of other interventions to help them access anti-osteoporotic
drug treatments.
In summary, this study demonstrated the first reimbursement guideline revision that
expanded diagnostic criteria for osteoporosis and extended the coverage period for anti-osteo-
porotic therapy was not associated with expanding the proportion of post-menopausal women
treated with anti-osteoporotic drugs. However, the second revision, which enlarged the eligi-
bility pool for reimbursement and further extended the coverage period for anti-osteoporotic
drug therapy, was associated with increase of anti-osteoporotic drugs. Although the second
revision allowed osteoporotic fracture patients to receive coverage for drug treatment for three
years, regardless of T-score, its association with increasing the proportion of osteoporotic frac-
ture patients treated with anti-osteoporotic drugs was observed only for women aged between
65 and 79 years. Thus, the impact of the policy was demonstrated in a limited population.
Long-term evaluation of the policy’s effect may be helpful to attain a more conclusive assess-
ment of the revision.
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